|
Adjuvant therapy utilization among stage III melanoma patients. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Agenus (I); Bluebird Bio; Dynavax Technologies (I); Exelixis (I); Juno Therapeutics; Mannkind; Newlink Genetics (I); Novartis; Provectus |
|
|
|
Stock and Other Ownership Interests - Ampio Pharmaceuticals (I); Johnson & Johnson |
|
|
|
Leadership - Trajectory Healthcare |
Stock and Other Ownership Interests - Trajectory Healthcare |
Patents, Royalties, Other Intellectual Property - Trajectory Healthcare |
|
|
|
Research Funding - Novartis; Novartis |
|
|
|
Stock and Other Ownership Interests - McKesson |
|
|
Employment - Novartis; Novartis (I) |
Stock and Other Ownership Interests - GlaxoSmithKline; Merck (I); Novartis; Novartis (I) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Merck (I) |
|
|
|
Stock and Other Ownership Interests - McKesson |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Celgene (I); Novartis |
Stock and Other Ownership Interests - Celgene; Corbus Pharmaceuticals; Incyte; Nektar; Novartis; OncoSec |
|
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; New Century Health |
Research Funding - Side-Out Foundation (Inst) |